Section Arrow
Quote
MESO.NASDAQ
- Mesoblast Limited
Quotes are at least 15-min delayed:2025/06/03 23:13 EDT
Last
 10.55
+0.17 (+1.64%)
Day High 
10.665 
Prev. Close
10.38 
1-M High
12.4 
Volume 
124.94K 
Bid
10.3
Ask
12.66
Day Low
10.41 
Open
10.42 
1-M Low
10.23 
Market Cap 
1.32B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 10.97 
20-SMA 11.19 
50-SMA 11.46 
52-W High 22 
52-W Low 5.78 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-89.15/-0.62
Enterprise Value
1.42B
Balance Sheet
Book Value Per Share
3.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
16.72M
Operating Revenue Per Share
0.06
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed：2025/06/03 23:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.